FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2961988991> ?p ?o ?g. }

• W2961988991 endingPage "1500" @default.
• W2961988991 startingPage "1490" @default.
• W2961988991 abstract "Background The use of immunotherapies in the treatment of metastatic cancers has significantly advanced oncology. However, due to safety concerns, solid organ transplant recipients (SOTRs) are routinely excluded from immunotherapy trials; thus, there is limited data for these agents in this population. Methods A systematic review was performed to evaluate the safety and efficacy of immunotherapies in SOTRs with metastatic cancers. Fisher's exact test and Kruskal-Wallis test were used for analysis. Results In total, 37% of patients experienced organ rejection, and 14% died as a result of graft rejection. Nivolumab was associated with the highest rejection rate (52.2%), followed by pembrolizumab (26.7%) and ipilimumab (25%; P = .1774). The highest rejection rate was seen in patients with kidney transplants (40.1%), then liver (35%) and heart (20%) transplants (P = .775), and 64% of patients succumbed to the progression of malignancy. For all cases, rates of progression or death secondary to disease were highest for ipilimumab (75%), followed by nivolumab (43%) and pembrolizumab (40%; P = .1892). The overall response rate was highest for pembrolizumab (40%), followed by nivolumab (30%) and ipilimumab (25%; P = .7929). Limitations The small sample size. Conclusion Physicians must be cautious when administering immunotherapy to SOTRs. However, rejection is not the most common cause for death in this population. The use of immunotherapies in the treatment of metastatic cancers has significantly advanced oncology. However, due to safety concerns, solid organ transplant recipients (SOTRs) are routinely excluded from immunotherapy trials; thus, there is limited data for these agents in this population. A systematic review was performed to evaluate the safety and efficacy of immunotherapies in SOTRs with metastatic cancers. Fisher's exact test and Kruskal-Wallis test were used for analysis. In total, 37% of patients experienced organ rejection, and 14% died as a result of graft rejection. Nivolumab was associated with the highest rejection rate (52.2%), followed by pembrolizumab (26.7%) and ipilimumab (25%; P = .1774). The highest rejection rate was seen in patients with kidney transplants (40.1%), then liver (35%) and heart (20%) transplants (P = .775), and 64% of patients succumbed to the progression of malignancy. For all cases, rates of progression or death secondary to disease were highest for ipilimumab (75%), followed by nivolumab (43%) and pembrolizumab (40%; P = .1892). The overall response rate was highest for pembrolizumab (40%), followed by nivolumab (30%) and ipilimumab (25%; P = .7929). The small sample size. Physicians must be cautious when administering immunotherapy to SOTRs. However, rejection is not the most common cause for death in this population." @default.
• W2961988991 created "2019-07-23" @default.
• W2961988991 creator A5017093116 @default.
• W2961988991 creator A5048000762 @default.
• W2961988991 creator A5055055308 @default.
• W2961988991 creator A5058092285 @default.
• W2961988991 date "2020-06-01" @default.
• W2961988991 modified "2023-10-01" @default.
• W2961988991 title "Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review" @default.
• W2961988991 cites W1517732299 @default.
• W2961988991 cites W1792627431 @default.
• W2961988991 cites W1922412259 @default.
• W2961988991 cites W1964106115 @default.
• W2961988991 cites W2044909087 @default.
• W2961988991 cites W2063712562 @default.
• W2961988991 cites W2070231299 @default.
• W2961988991 cites W2126453999 @default.
• W2961988991 cites W2132554273 @default.
• W2961988991 cites W2137960096 @default.
• W2961988991 cites W2143902379 @default.
• W2961988991 cites W2161374186 @default.
• W2961988991 cites W2166662937 @default.
• W2961988991 cites W2210105857 @default.
• W2961988991 cites W2223436478 @default.
• W2961988991 cites W2281172593 @default.
• W2961988991 cites W2291675306 @default.
• W2961988991 cites W2295766629 @default.
• W2961988991 cites W2300181798 @default.
• W2961988991 cites W2303235652 @default.
• W2961988991 cites W2394658251 @default.
• W2961988991 cites W2510073371 @default.
• W2961988991 cites W2512287004 @default.
• W2961988991 cites W2516629980 @default.
• W2961988991 cites W2529221862 @default.
• W2961988991 cites W2530067375 @default.
• W2961988991 cites W2535835299 @default.
• W2961988991 cites W2560460441 @default.
• W2961988991 cites W2578082697 @default.
• W2961988991 cites W2592187743 @default.
• W2961988991 cites W2593637053 @default.
• W2961988991 cites W2604481266 @default.
• W2961988991 cites W2678992970 @default.
• W2961988991 cites W2684657709 @default.
• W2961988991 cites W2734991617 @default.
• W2961988991 cites W2737651375 @default.
• W2961988991 cites W2737895097 @default.
• W2961988991 cites W2739983085 @default.
• W2961988991 cites W2740910678 @default.
• W2961988991 cites W2753432434 @default.
• W2961988991 cites W2761384929 @default.
• W2961988991 cites W2763543378 @default.
• W2961988991 cites W2770613715 @default.
• W2961988991 cites W2770760892 @default.
• W2961988991 cites W2774961787 @default.
• W2961988991 cites W2780967330 @default.
• W2961988991 cites W2805968856 @default.
• W2961988991 cites W2808822420 @default.
• W2961988991 cites W2883959012 @default.
• W2961988991 cites W2886258754 @default.
• W2961988991 cites W2886851488 @default.
• W2961988991 cites W2888041146 @default.
• W2961988991 cites W2890878507 @default.
• W2961988991 cites W2897435840 @default.
• W2961988991 cites W2898330673 @default.
• W2961988991 cites W2898419360 @default.
• W2961988991 cites W2899970113 @default.
• W2961988991 doi "https://doi.org/10.1016/j.jaad.2019.07.005" @default.
• W2961988991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31302190" @default.
• W2961988991 hasPublicationYear "2020" @default.
• W2961988991 type Work @default.
• W2961988991 sameAs 2961988991 @default.
• W2961988991 citedByCount "98" @default.
• W2961988991 countsByYear W29619889912019 @default.
• W2961988991 countsByYear W29619889912020 @default.
• W2961988991 countsByYear W29619889912021 @default.
• W2961988991 countsByYear W29619889912022 @default.
• W2961988991 countsByYear W29619889912023 @default.
• W2961988991 crossrefType "journal-article" @default.
• W2961988991 hasAuthorship W2961988991A5017093116 @default.
• W2961988991 hasAuthorship W2961988991A5048000762 @default.
• W2961988991 hasAuthorship W2961988991A5055055308 @default.
• W2961988991 hasAuthorship W2961988991A5058092285 @default.
• W2961988991 hasConcept C121608353 @default.
• W2961988991 hasConcept C126322002 @default.
• W2961988991 hasConcept C143998085 @default.
• W2961988991 hasConcept C2777701055 @default.
• W2961988991 hasConcept C2779984678 @default.
• W2961988991 hasConcept C2780030458 @default.
• W2961988991 hasConcept C2780057760 @default.
• W2961988991 hasConcept C2781433595 @default.
• W2961988991 hasConcept C2908647359 @default.
• W2961988991 hasConcept C31760486 @default.
• W2961988991 hasConcept C535046627 @default.
• W2961988991 hasConcept C71924100 @default.
• W2961988991 hasConcept C99454951 @default.
• W2961988991 hasConceptScore W2961988991C121608353 @default.
• W2961988991 hasConceptScore W2961988991C126322002 @default.
• W2961988991 hasConceptScore W2961988991C143998085 @default.

• next